To the Editor We read with interest the Editorial by Wagle Shukla1 regarding our article.2 As discussed in the Editorial, there is a significant unmet need in the treatment of levodopa-induced dyskinesia (LID). It also highlights the benefits of ADS-5102 (amantadine) in the treatment of LID as well as some limitations of the EASE LID Study, which was the first study to demonstrate an oral treatment that reduced both LID and OFF time in Parkinson disease.2 We would like to clarify the following aspects.
Pahwa R, Hauser RA. ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia. JAMA Neurol. 2017;74(12):1507–1508. doi:10.1001/jamaneurol.2017.3205
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: